MAM
RVMD icon

Marquette Asset Management’s Revolution Medicines RVMD Stock Holding History

Marquette Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75K Hold
20
– – ﹤0.01% 471
2026
Q1 		$1.95K Hold
20
– – ﹤0.01% 551
2025
Q4 		$1.59K Buy
+20
New +$1.31K ﹤0.01% 518

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Marquette Asset Management's RVMD Position: Q2 2026 in Review

Marquette Asset Management held its Revolution Medicines (RVMD) position steady in Q2 2026 at 20 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Marquette Asset Management first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Marquette Asset Management held 20 shares of Revolution Medicines worth $3.75K as of Q2 2026.
  • Marquette Asset Management left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #471 holding.
  • Marquette Asset Management first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.